The University of Texas MD Anderson Cancer Center is a comprehensive cancer center in Houston, Texas. It is the largest cancer center in the U.S. and one of the original three comprehensive cancer centers in the country.

During the past decade, University of Texas/MD Anderson Cancer Center Dept of Onc. conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Texas/MD Anderson Cancer Center Dept of Onc." #1 sponsor was "Novartis Pharmaceuticals" with 4 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Array BioPharma" with 2 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored and "Genentech, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Texas/MD Anderson Cancer Center Dept of Onc." #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "University of Texas/MD Anderson Cancer Center Dept of Onc." are "AML" (1 trials), "Advanced and Selected Solid Tumors" (1 trials), "Breast Cancer" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "University of Texas/MD Anderson Cancer Center Dept of Onc." in a lesser frequency.

Most popular intervention types in "University of Texas/MD Anderson Cancer Center Dept of Onc." are "Drug" (12 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "MEK162" (2 trials), "Tiragolumab" (2 trials), "Atezolizumab Matching Placebo" (1 trials) and "BYL719" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Texas/MD Anderson Cancer Center Dept of Onc." are 11 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "University of Texas/MD Anderson Cancer Center Dept of Onc.". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in University of Texas/MD Anderson Cancer Center Dept of Onc., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in University of Texas/MD Anderson Cancer Center Dept of Onc., 10 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".